Search

everythinglearnresearchcommunity

for

Search:↓

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.

Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.

The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.

The excimer laser is a promising and safe treatment for frontal fibrosing alopecia.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Talquetamab may cause hair loss and skin issues.

Upadacitinib effectively treats psoriasiform eczema and some related conditions.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Adalimumab may cause severe hair loss in some patients.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.

Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.

Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.

Alefacept showed some effectiveness for alopecia areata but needs more research.

Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

The document did not conclude on apremilast's effectiveness for severe alopecia areata.

Olumiant should be covered for severe alopecia areata if certain conditions are met.